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CLINICAL EXPERIENCE OF GRANULOCYTE TRANSFUSION THERAPY IN
MANAGEMENT OF NEUTROPENIA RELATED INFECTIONS IN A
TERTIARY CARE CENTER
Sohini Chakraborty, Ruchi Chaudhary, Waseem Iqbal, Sonamani
Ngangbam, Shobha Badiger, Tadele Hailu, B.R. Prathip, Sharat
Damodar, K.S. Nataraj, Sunil Bhat. Mazumdar Shaw Cancer Center,
Narayana Health City, Bangalore, India
E-mail address: sunilbhat_9@hotmail.com (S. Bhat).
Background: Granulocyte transfusions have recently gained popularity for
the treatment of severe infections in neutropenic patients which do not
respond to conventional antimicrobial therapies and recombinant growth
factors. We conducted the present study to determine the clinical course of
patients with neutropenia related infection receiving granulocyte trans-
fusions in our center and to assess its efﬁcacy in resolution of infections.
Methods: Retrospective analysis of all pediatric patients up to 18 years of
age with neutropenia and infection receiving granulocyte transfusions in
our hospital between January 2015 and July 2016.
Results: Twenty one pediatric patients with severe neutropenia related
infections unresponsive to appropriate antimicrobial agents were included
in the study. They received a total of 57 granulocyte transfusions. The study
population comprised of 10 females (47.6%) and 11 males (52.4%). Median
age of the study population was 9 yrs (5 months-16 years). 13 patients
suffering from nonmalignant hematological diseases and 8 patients with
malignant diseases were included in the study population. Voluntary
healthy donors were used after granulocyte mobilization using gran-
ulocyte colony- stimulating factor (G-CSF) and dexamethasone. The me-
dian donor WBC count before leukapheresis was 31.9  109 /L and the
mean donor granulocyte yield was 8.9  1010 /L. Seven patients had
localized infection while 14 had sepsis. Causative organisms could be
isolated in 16 cases out of which gram negative bacillus was isolated in 15
(93.75%). Median duration of neutropenia, antimicrobial therapy and G-
CSF administration before granulocyte transfusion was 11 days (range 2-
34), 10 days (range 3-20) and 9 days (range 2-20) respectively. Patients
received amean of 2.85 (range 1-8) granulocyte transfusions andmean cell
dose of 2.7  1010 granulocytes. Ten of the total twenty one patients
included had a favorable response and recovered from the infection.
Granulocyte transfusions were generally well tolerated inmost of the cases
except for one episode of transfusion associated acute lung injury.
Conclusion: Granulocyte transfusions seem to be a clinically useful and
generally safe adjunct in management of severe neutropenia related
infections.
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BLOOD AND BLOOD PRODUCTS TRANSFUSION AUDIT: CURRENT
PRACTICES AND LACUNAE IN BLOOD AND BLOOD PRODUCT
TRANSFUSION AMONG HOSPITALIZED CHILDREN
Purva Kanvinde, Mukesh Agrawal. Seth G S Medical College and KEM
Hospital, India
Transfusion audits are most effective tools to detect inappropriate blood
product transfusion practices and suggest remedial measures to ensure
safe and effective use of this precious product in health-care.
Objectives: Present study was designed to assess current practices
regarding blood product transfusions in childrenwith special emphasis on
the appropriateness of these transfusions.
Materials & Method: Present study was a prospective study conducted
over a period of 22 months from January 2013 to October 2014. Each
episode of transfusion was analyzed and divided into appropriate and
inappropriate according to the type of blood component, the clinical and
hematological indication. Data was reviewed according to British Com-
mittee for Standards in Hematology and American Association of Blood
Bank guidelines.Results: In this study, a total 741 transfusions were used in 327 cases,
including 449 packed red blood cells (60.6%), 148 Fresh frozen plasma
(20.0%), 140 (18.9%) platelets and 4 (0.5%) whole blood transfusions.
Appropriate usage of blood and blood products was 70.5%. Most inap-
propriately used was FFP (39.2% of FFP transfusions), followed by Packed
RBCs (28.7%) and Platelets (22.9%). Packed RBCs transfusions were used
most commonly for sepsis with/without DIC (25.2%), followed by nutri-
tional anemia (20.7%) Packed RBC transfusions were used most inappro-
priately for nutritional anemia (49.5%) and sepsis (46.9%). FFP transfusions
were used maximally for the indication of sepsis with/without DIC (43.2%),
followed by perioperative indications (21.6%). FFP transfusions were most
inappropriate for Dengue (68.8%) and perioperative indications (53.1%).
Platelet transfusions were most commonly used for Aplastic anemia (45%)
followed by sepsis (24.3%) Platelet transfusions weremost inappropriate in
Dengue cases (85%) and Idiopathic thrombocytopenic purpura (50%).
Conclusion: Present study concludes that in the study population, about
one-third of all blood component transfusions used in study center are
inappropriate. This study suggests establishment of set protocols for
requisition of blood component transfusions in the study set-up to mini-
mize irrational and unsafe use of these products.
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Richa Jain 1, Amita Trehan 1, M.R. Shivaprakash 2, Arunaloke
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Introduction: Incidence of invasive fungal infections in children with
hematological malignancies is increasing. We present clinical features and
outcome of children with fungal brain abscess in acute lymphoblastic
leukemia (ALL), an entity which traditionally has dismal outcomes.
Methods: Eighteen months data is presented. Total 160 new ALL patients
were recruited. Thirteen developed proven fungal infection. Details of
children with fungal CNS infection were retrieved and analyzed.
Results: Five children had fungal brain abscesses. B-cell ALL:T-cell was 4:1.
Three childrenwere standard risk, 2 intermediate risk. All were on intense
chemotherapy including steroids; 4 induction, 1 intensiﬁcation. Clinical
presentation: Prolonged neutropenia: 100%; fever: 100%; altered senso-
rium/seizures seen in 80% (4/5). Duration of neutropenia: 16 days (14-23).
Primary focus was lung in 4, ear in 1. Brain abscess was single in 2, multiple
in 3 children. Meningitis was present in 2. All children underwent surgery
(burr-hole drainage:4, excision:1). Culture/PCR proven fungus was seen in
all: Aspergillus in 4; Mucor:1. Elevated serum galactomannan seen in 66%.
Combination antifungals were given for aspergillus: Amptotericin (plain/
liposomal)& voriconazole for 10 days, followed by voriconazole alone for 6
months. Single mucor patient received amphotericin for 12 months.
Overall survival at 10 months: 80%; event free survival: 40% (events-
death:1, defaulter:1, cortical blindness:1). Three children are continuing
chemotherapy.
Conclusion: Mortality rate in fungal brain infections in children is re-
ported to be 65%. Better outcomes in our patients can be attributed to
multimodality therapy and early initiation of antifungal therapy along
with judicious management of chemotherapy.
Keywords: Aspergillus, acute lymphoblastic leukemia, brain abscess,
invasive aspergillosis
Table 1
Patient Characteristics
Patient characteristics N¼5
Age 7.5 years (3-11)
Sex (M: F) 4:1
Phase of therapy Induction (week 3-5):4
Delayed Intensiﬁcation: 1
Presenting features Fever: 100%
Seizures: 80%
Altered sensorium: 20%
Preceding focus (100%) Pneumonia: 4
ASOM: 1
Neutropenia (100%) Median duration 16 days (14-23)
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ROLE OF CARDIAC BIOMARKERS IN DETECTION OF MYOCARDIAL
DAMAGE IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES
TREATED WITH ANTHRACYCLINES
Sunil Kumar Singh 1, Rimjhim Sonowal 1, Vikas Agrawal 2, Vineeta
Gupta 1. 1Department of Pediatrics, Institute of Medical Sciences, Banaras
Hindu University, Varanasi, India; 2Department of Cardiology, Institute of
Medical Sciences, Banaras Hindu University, Varanasi, India
Objective: Anthracyclines exposure during treatment of childhood malig-
nancies poses a high risk for development of late cardiotoxicity. Car-
diotoxicity is usually diagnosed when patient is symptomatic with
progressive cardiac dysfunction. Early detection is important to institute
early therapeutic interventions to improve outcome. Aim of present study
was to evaluate cardiac troponin T (cTnT), N-terminal probrain natriuretic
peptide (NT-pro BNP) and creatinine kinase MB isoenzyme (CK-MB) and
echocardiography in the detection of cardiac abnormalities in asymptom-
atic children treated for hematological malignancies with anthracyclines.
Methods: Serum levels of cTnT, NT-pro BNP and CK-MB were measured in
40 survivors (26 males and 14 females) of hematological malignancies (20
high risk acute lymphoblastic leukemia and 20 Hodgkin lymphoma pa-
tients). All patients had received >200 mg/m2 cumulative dose of
anthracyclines and were more than 2 years post chemotherapy. 30 healthy
children were taken as controls. Echocardiography using M-mode and
Doppler measurements were performed on same day as blood in-
vestigations. Study was approved by Institute Ethics committee.
Results: Serum levels of NT-proBNP were signiﬁcantly higher in patients
compared to controls (48.69 ± 20.36 vs 5.08 ± 3.74 pg/ml; p value <0.01). 6
of the patients had left ventricular (LV) dysfunction with mean NT-proBNP
levels of 67.29 ± 22.73 pg/ml which was signiﬁcantly higher than patients
who had normal LV function (mean NT-proBNP levels of 36.19 ± 21.93 pg/
ml. Levels correlated inversely with fractional shortening and ejection
fraction and positively with the cumulative dose of anthracyclines. No
difference was observed between males and females. Serum levels of cTnT
and CK-MB were higher in the patients but they were not statistically
signiﬁcant.
Conclusions: NT-pro-BNP is a sensitive test and correlates with cardiac
function It can be used as a useful biomarker for early detection of
anthracycline cardiotoxicity.TM_SC-1_V1.5
EVALUATION OF SERUM PROCALCITONIN, SERUM INTERLEUKIN-6 AND
INTERLEUKIN-8 TO PREDICT RISK GROUPS IN CHILDREN WITH FEBRILE
NEUTROPENIA AND CANCER
Nuthan Kumar, Fellow 1, Supriya Suresh Gujjar 1, Arathi Srinivasan, Junior
Consultant 2, Padma Keerthiga, Senior Consultant 3, Julius Xavier Scott,
Senior Consultant 4. 1Department of Pediatric Hematology and Oncology,
Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, India;
2Department of Pediatric Hematology and Oncology, Kanchi Kamakoti
Childs Trust Hospital, Chennai, Tamil Nadu, India; 3Department of
Biochemistry, Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu,
India; 4Department of Pediatric Hematology and Oncology, Kanchi
Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, IndiaBackground: Early diagnosis of sepsis in childrenwith febrile neutropenia
remains difﬁcult due to non-speciﬁc clinical and laboratory signs of
infection. There is a need to assess the utility of inﬂammatory markers in
clinical risk assessment for their ability to discriminate between low-risk
and high-risk neutropenic patients since presently there is an insufﬁcient
data to recommend their routine use.
Study design andmethodology: This is a prospective study of children on
therapy admitted with febrile neutropenia between 2015-2016 and
sampled for markers at admission. The febrile neutropenia episodes were
categorized into two groups - Group I:no focus of infection and Group
II:clinically/microbiologically documented infection. Statistical analysis for
comparison were performed using z-test and Receiver operating curves at
various cut-off levels.
Results: A total of 46 episodes of febrile neutropenia were analysed. 76%
were categorized as group I and 24% as group II. The mean value of PCT in
group II was higher (28.07 ng/ml) as compared to group I (1.03ng/ml)
though there was no signiﬁcant statistical difference. At a cut off level of 2
ng/ml for PCT, sensitivity of 63%, speciﬁcity of 91%, PPV of 70%, NPV of 88%
were observed. There was no signiﬁcant difference in the IL-6 and IL-8
levels between both the groups. But at an optimal cut off value of 50 pg/ml,
IL-6 had a NPV of 80% and at a cut off level of 130 pg/ml, IL-8 had a NPV of
73%, however with low sensitivity and speciﬁcity.
Conclusion: IL-6, IL-8 and PCT can be utilized to deﬁne a group of patients
with a low risk of sepsis in view of their favorable NPV. The utility of these
biomarkers together can facilitate early discharge from the hospital, and
the use of oral antimicrobial therapy in turn reducing the cost of therapy
especially in a developing country.
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VITAMIN D STATUS IN NEWLY DIAGNOSED PEDIATRIC ONCOLOGY
PATIENTS AT A TERTIARY CARE HOSPITAL
Purvi Kadakia, Maaz Ahmed, Dhwani Shah, Girish Rajadhyaksha. Department
of Medical Oncology, TNMC & B.Y.L Nair Hospital, India
Introduction: Vitamin D or 25-Hydroxycholecalciferol, an important
immunomodulator, is commonly found to be deﬁcient in healthy young
children as well as in adolescent age group with prevalence of about 50 to
90 % in India. Vitamin D has important anticancer effects such as poten-
tiating apoptosis, prevents proliferation and inhibits angiogenesis. There is
paucity of data on status of vitamin D levels in Pediatric oncology patients
and recently its deﬁciency has been suggested to be associated with can-
cer. Our aim was to study status of vitamin D level in newly diagnosed
Pediatric Oncology patients at a tertiary centre.
Material and Methods: The study included all the newly diagnosed Pe-
diatric oncology cases (solid and hematological neoplasm) between the
age group of 1 to 18 years at a tertiary care centre in a metropolitan city in
India over a period of 12 months from June 2015 to July 2016. The vitamin
D level was done at the time of diagnosis after informed consent from
parents and assent from children above seven years was obtained. Two ml
of fasting blood was collected in a plain bulb which was analysed for 25-
hydroxy cholecalceferol by ELISA method. The age, sex, diagnosis and
vitamin D level at time of diagnosis was recorded in case record form. The
vitamin D level was stratiﬁed as deﬁciency, insufﬁciency, sufﬁciency and
toxicity level as per classiﬁcation by US endocrine society. The data anal-
ysis was done with SSPS software.
Results: Forty one patients were enrolled in the study of which 70.7% were
males. Ten (24.4%) were in the age group of 1 to 5 years, 27 (65.9%)
belonged to 5-14 years and only 4 belonged to 14- 18 years. The study
revealed 32 (78%) children had vitamin D level below 20 ng/dl that is
deﬁcient, 5 (12.19%) patients were between 21- 29 ng/ml indicating
insufﬁciency and only 4 (9.75%) were sufﬁcient which was vitamin D level
more than 30ng/dl. Among 32 deﬁcient patients, nine (28 .4%) were in the
age group of 1 to 5 years, 19 (59.3%) belonged to 5-14 years and 71.1% were
males. Among the subgroup of sufﬁcient vitamin D level, all were males.
Pre B cell acute lymphocyte leukemia (28%) followed by Hodgkin's lym-
phoma (12%) were common malignancies among deﬁcient subgroup.
Conclusion: There is a high prevalence of Vitamin D deﬁciency and
insufﬁciency (90.19%) among Pediatric oncology patients at the time of
diagnosis as described in our cohort. The impact of vitamin D screening
